Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Cellular and Molecular Biology

Can TILs supplement the TNM staging system (as TNM-Immune)?

British Journal of Cancer volume 129, pages 739–740 (2023)Cite this article

Subjects

We read with interest the recent review article by Brummel et al. [1] on the prognostic significance of tumour-infiltrating lymphocytes (TILs) across various cancer types. We congratulate the authors for this timely review of the topic, and we would like to emphasise the emerging, important role of TILs in tumour characterisation, which was not highlighted in their review. Incorporation of TILs as a modifier to supplement the commonly used tumour-node-metastasis (TNM) classification, designated as TNM-Immune staging system, has been proposed recently [2]. It is widely accepted that different cancers with the same TNM stage may present with extreme variations in their pre-existing adaptive immunity [3]. Thus, incorporating a parameter which assesses immune response in the TNM system seems clinically relevant in predicting tumour behaviour. Such a proposal allows incorporation of the immune response in cancer classification and even in clinical therapeutical decision making.

The prognostic significance of the TNM-Immune staging system has been introduced previously in some studies [4,5,6] including our recent study on oropharyngeal cancer published in British Journal of Cancer [6]. In our multicentre study on early-stage oral tongue cancer [5], the TNM-Immune staging system based on incorporation of an overall score of TILs, showed a prognostic value superior to that of the routine TNM classification (American Joint Committee on Cancer eighth edition, AJCC 8). In breast cancer, emerging evidence indicates that TILs can up- or downgrade prognosis related to the stage of the AJCC 8, so that stage I patients with low TILs may have a worse survival than stage II patients with high TILs. This has been recently reported by de Jong et al. [7] who found that stage II cases with high infiltration of stromal TILs were associated with a better survival than stage IB cases presenting with low infiltration of TILs. In colon cancer, findings from a large series of cases strongly supported implementation of the immunoscore (densities of CD3 and CD8 positive cells) into the TNM-Immune staging system [8]. In lung cancer, TNM-Immune staging has shown a promising prognostic value [9]. In addition, immunoscore based on the analysis of subsets of TILs added a significant prognostic impact to the TNM staging of lung cancer [4].

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Brummel K, Eerkens AL, de Bruyn M, Nijman HW. Tumour-infiltrating lymphocytes: from prognosis to treatment selection. Br J Cancer. 2023;128:451–8.

    Article  CAS  PubMed  Google Scholar 

  2. Taube JM. Emerging immunologic biomarkers: setting the (TNM-immune) stage. Clin Cancer Res. 2014;20:2023–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity. 2020;52:55–81.

    Article  CAS  PubMed  Google Scholar 

  4. Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, et al. Stromal CD8+ T-cell density – a promising supplement to TNM staging in non-small cell lung cancer. Clin Cancer Res. 2015;21:2635–43.

    Article  PubMed  Google Scholar 

  5. Almangush A, Bello IO, Heikkinen I, Hagstrom J, Haglund C, Kowalski LP, et al. Improving risk stratification of early oral tongue cancer with TNM-immune (TNM-I) staging system. Cancers (Basel). 2021;13:3235.

    Article  PubMed  Google Scholar 

  6. Almangush A, Jouhi L, Atula T, Haglund C, Makitie AA, Hagstrom J, et al. Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group. Br J Cancer. 2022;126:1589–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. de Jong VMT, Wang Y, Ter Hoeve ND, Opdam M, Stathonikos N, Jozwiak K, et al. Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)adjuvant systemic therapy. J Clin Oncol. 2022;40:2361–74.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128–39.

    Article  PubMed  Google Scholar 

  9. Kilvaer TK, Paulsen EE, Andersen S, Rakaee M, Bremnes RM, Busund LR, et al. Digitally quantified CD8 + cells: the best candidate marker for an immune cell score in non-small cell lung cancer? Carcinogenesis. 2020;41:1671–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Helsinki, P.O. Box 21, FI-00014, Helsinki, Finland

    Alhadi Almangush

  2. Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland

    Alhadi Almangush & Antti A. Mäkitie

  3. Institute of Biomedicine, Pathology, University of Turku, Kiinamyllynkatu 10 D 5035, 20520, Turku, Finland

    Alhadi Almangush & Ilmo Leivo

  4. Faculty of Dentistry, Misurata University, Misurata, Libya

    Alhadi Almangush

  5. Department of Otorhinolaryngology – Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, P.O. Box 263, FI-00029 HUS, Helsinki, Finland

    Antti A. Mäkitie

  6. Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

    Antti A. Mäkitie

  7. Turku University Central Hospital, 20521, Turku, Finland

    Ilmo Leivo

Authors
  1. Alhadi Almangush
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antti A. Mäkitie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ilmo Leivo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The three authors wrote, revised, and approved the final version of the manuscript.

Corresponding author

Correspondence to Alhadi Almangush.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Almangush, A., Mäkitie, A.A. & Leivo, I. Can TILs supplement the TNM staging system (as TNM-Immune)?. Br J Cancer 129, 739–740 (2023). https://doi.org/10.1038/s41416-023-02368-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-023-02368-x

Search

Advanced search

Quick links